Stay updated on MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.
Latest updates to the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedSeveral key URLs related to genetics, melanoma, and clinical trials have been removed, which may impact access to important medical information and resources.SummaryDifference4%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe website has been updated to version 2.12.2, with new additions including links to genetics resources, clinical trial documents, and drug information for melanoma treatments such as Trametinib, Dabrafenib, and Pembrolizumab.SummaryDifference4%
- Check33 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.1%
- Check41 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential improvements or features.SummaryDifference0.1%
- Check62 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.1%
- Check70 days agoChange DetectedThe website has been updated to Revision v2.11.0, while the previous version v2.10.5 has been removed, along with a notice regarding delays in displaying study record information.SummaryDifference0.7%
Stay in the know with updates to MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.